Streetbeat News

Products Services

ARWR

Arrowhead Pharmaceuticals presented promising preclinical data on their investigational obesity treatment, ARO-INHBE, at the ADA conference. The data showed significant gene silencing and potential benefits in weight and fat reduction. Arrowhead plans to seek regulatory clearance for clinical trials in late 2024.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:45 am

RGLS

Regulus Therapeutics shares are trading higher following the announcement of positive topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:43 am

KURA

Kura Oncology (NASDAQ:KURA) presented preclinical data at the American Diabetes Association's 84th Scientific Sessions, showing the potential of their menin inhibitor, ziftomenib, in treating diabetes. The data demonstrated significant glycemic control and beta-cell proliferation, suggesting further evaluation is warranted.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:43 am

VKTX

Viking Therapeutics (NASDAQ:VKTX) presented preclinical data on its dual amylin and calcitonin receptor agonists (DACRAs) at the American Diabetes Association's 84th Scientific Sessions. The data showed significant reductions in body weight and improvements in metabolic markers in both lean rats and diet-induced obese mice, supporting the continued development of these compounds for obesity treatment.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:39 am

DCGO

DocGo Inc. (NASDAQ:DCGO) has secured five new contracts to provide various healthcare services, including remote patient monitoring, virtual care management, and chronic care management. These contracts expand DocGo's reach in delivering quality healthcare services.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:36 am

MNY

MoneyHero Group has reiterated its FY24 revenue guidance of $100M, reporting a 24% YoY revenue increase to $22.2M in Q1. The company attributes its growth to strategic initiatives and strong performance across core markets, despite seasonal challenges. Key growth drivers include insurance brokerage, strong partner relationships, and the Creatory platform. The company is investing in growth and market share expansion, with a focus on operational efficiencies and higher margin products.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:34 am

ALT

Altimmune shares are trading higher following the presentation of data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide at the American Diabetes Association's 84th Scientific Sessions.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:34 am

AAPL

COIN

DJT

META

NVDA

QQQ

RMD

SPY

Nasdaq futures slipped as Nvidia's sell-off continued, while S&P 500 futures held up. Analysts suggest that tech stock valuations may go parabolic, making it a good time to sell. SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ ETF (QQQ) showed mixed premarket performance. Key stocks in focus include Nvidia, Coinbase, Apple, Meta, Trump Media & Technology Group, and ResMed.

Portfolio Pulse from Shanthi Rexaline

June 24, 2024 | 11:33 am

CKPT

Checkpoint Therapeutics has reached an agreement with the FDA regarding the resubmission of its Biologics License Application (BLA) for Cosibelimab. This development is crucial for the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:32 am

TRDA

Entrada Therapeutics (NASDAQ:TRDA) announced a $100M registered direct offering to fund ongoing clinical development. The offering includes 3.4M shares at $14.85/share and is expected to close by June 25, 2024. Proceeds will support Phase 2 trials and R&D activities.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:20 am